Advertisement

Introduction to the Pharmacology of Ergot Alkaloids and Related Compounds as a Basis of Their Therapeutic Application

  • B. Berde
  • E. Stürmer
Part of the Handbook of Experimental Pharmacology / Handbuch der experimentellen Pharmakologie book series (HEP, volume 49)

Abstract

This chapter, rather unorthodox for a volume of the Handbook of Experimental Pharmacology, is not intended as a summary of the wealth of information accumulated in this book. It is an attempt at a compact synopsis to help those teaching pharmacology or writing a textbook of pharmacology not to overlook the essential chemical and biological basis of the therapeutically most important compounds and those of their activities which are believed to be relevant for their therapeutic effects.

Keywords

Migraine Attack Ergot Alkaloid Prolactin Secretion Lysergic Acid Plasma Prolactin Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aellig, W.H., Berde, B.: Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed. Brit. J. Pharmacol. 36, 561–570 (1969)Google Scholar
  2. Ahlquist, R.P.: A study of the adrenotropic receptors. Amer. J. Physiol. 153, 586–600 (1948)PubMedGoogle Scholar
  3. Altman, S.G., Waltman, R., Lubin, S., Reynolds, S.R.M.: Oxytocic and toxic actions of dihydroergotamine-45. Amer. J. Obstet. Gynec. 64, 101–109 (1952)PubMedGoogle Scholar
  4. Benzi, G., De Bernardi, M., Manzo, L., Ferrara, A., Panceri, P., Arrigoni, E., Berte, F.: Effect of lysergide and nimergoline on glucose metabolism investigated on the dog brain isolated in situ. J. pharm. Sci. 61, 348–352 (1972)PubMedGoogle Scholar
  5. Berde, B.: Recent progress in the elucidation of the mechanism of action of ergot compounds used in migraine therapy. Med. J. Aust. Spec. Suppl. 2, 15–26 (1972)Google Scholar
  6. Berde, B.: Human plasma levels of anti-migraine drugs contrasted with their active concentrations in isolated organ systems. The Bergen Migraine Symposium, Bergen, 4–6 June, 1975Google Scholar
  7. Berde, B., Cerletti, A., Dengler, H.J., Zoglio, M.A.: Studies of the interaction between ergot alkaloids and xanthine derivatives. In: Background to Migraine. Cochrane, A.L. (ed.), pp. 80–102. London: William Heinemann Medical Books 1970Google Scholar
  8. Berde, B., Rothlin, E.: Über die Uteruswirkung hydrierter Mutterkornalkaloide an Kaninchen und Katzen vor, während und nach der Geburt. Helv. physiol. pharmacol. Acta 11, 274–282 (1953)PubMedGoogle Scholar
  9. Berde, B., Saameli, K.: Evaluation of substances acting on the uterus. In: Methods in Drug Evaluation. Mantegazza, P., Piccinini, F. (eds.), pp. 481–514. Amsterdam: North Holland Publ. 1966Google Scholar
  10. Besser, G.M., Parke, L., Edwards, C.R.W., Forsyth, I.A., McNeilly, A.S.: Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Brit. med. J. 3, 669–672 (1972)PubMedGoogle Scholar
  11. Billeter, E., Fluckiger, E.: Evidence for a luteolytic function of prolactin in the intact cyclic rat using 2-Br-α-Ergokryptine (CB 154). Experientia (Basel) 27, 464–465 (1971)Google Scholar
  12. Boismare, F., Lorenzo, J.: Study of the protection afforded by nicergoline against the effects of cerebral ischemia in the cat. Arzneimittel-Forsch. 25, 410–413 (1975)Google Scholar
  13. Bradley, P.B., Briggs, I.: Ergot alkaloids and related substances. In: Neuropoisons—Their Pathophysiological Actions. Poisons of Plant Origin. Simpson, L.L., Curtis, D.R. (eds.), Vol. II, pp. 249–296. New York-London: Plenum Press 1974Google Scholar
  14. Brody, T.M., Diamond, J.: Blockade of the biochemical correlates of contraction and relaxation in uterine and intestinal smooth muscle. Ann. N.Y. Acad. Sci. 139, 772–780 (1967)PubMedGoogle Scholar
  15. Brown, G.L., Dale, Sir Henry: The pharmacology of ergometrine. Proc. roy. Soc. B. 118, 446–477 (1935)Google Scholar
  16. Brugger, J.: Die isolierte Samenblase des Meerschweinchens als biologisches Testobjekt zur quantitativen Differenzierung der sympathikolytischen Wirkung der genuinen Mutterkornalkaloide und ihrer Dihydroderivate. Helv. physiol. pharmacol. Acta 3, 117–134 (1945)Google Scholar
  17. Calne, D.B., Kartzinel, R., Shoulson, I.: An ergot derivative in the treatment of Parkinson’s disease. Postgrad. med. J. 52 (Suppl. 1), 81–82 (1976)PubMedGoogle Scholar
  18. Carpi, A., Virno, M.: The action of ergotamine on the intracranial venous pressure and on the cerebral venous outflow of the dog. Brit. J. Pharmacol. 12, 232–239 (1957)PubMedGoogle Scholar
  19. Cerletti, A., Berde, B., Doepfner, W., Emmenegger, H., Konzett, H., Schalch, W.R., Taeschler, M., Weidmann, H.: Deseril® (methysergide, UML-491), a specific serotonin antagonist. Sci. Exhibit 6th Internat. Congr. Int. Medicine, Basle, 24–27 August, 1960Google Scholar
  20. Cerletti, A., Emmenegger, H., Enz, A., Iwangoff, P., Meier-Ruge, W., Musil, J.: Effects of ergot DH-alkaloids on the metabolism and function of the brain. An approach based on studies with DH-ergonine. In: Central Nervous System — Studies on Metabolic Regulation and Function. Genazzani, E., Herken, H. (eds.), pp. 201–212. Berlin-Heidelberg-New York: Springer 1973Google Scholar
  21. Chu, D., Owen, D.A.A., Stürmer, E.: Effects of ergotamine and dihydroergotamine on the resistance and capacitance vessels of skin and skeletal muscle in the cat. Postgrad. med. J. 52 (Suppl. 1), 32–36 (1976)Google Scholar
  22. Cleary, R.E., Crabtree, R., Lemberger, L.: The effect of lergotrile on galactorrhea and gonadotropin secretion. J. clin. Endocr. 40, 830–833 (1975)PubMedGoogle Scholar
  23. Clemens, J.A., Smalstig, E.B., Shaar, C.J.: Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action. Acta endocr. (Kbh.) 79, 230–237 (1975)Google Scholar
  24. Corrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P., Ungerstedt, U.: Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons. Letters to the Editor. J. Pharm. Pharmacol. 25, 409–412 (1973)Google Scholar
  25. Del Pozo, E., Flückiger, E.: Prolactin inhibition: experimental and clinical studies. In: Human Prolactin. Pasteels, J.L., Robyn, C. (eds.), pp. 291–301. Amsterdam: Excerpta Medica 1973Google Scholar
  26. Del Pozo, E., Goldstein, M., Friesen, H., Brun Del Re, R., Eppenberger, U.: Lack of action of prolactin suppression on the regulation of the human menstrual cycle. Amer. J. Obstet. Gynec. 123, 719–723 (1975)PubMedGoogle Scholar
  27. Del Pozo, E., Brun del Re, R., Varga, L., Friesen, H.: The inhibition of prolactin secretion in man by CB-154 (2-Br-α-ergocryptine). J. clin. Endocr. 35, 768–771 (1972)PubMedGoogle Scholar
  28. Depoortere, H, Loew, D.M., Vigouret, J.M.: Neuropharmacological studies on Hydergine®. Triangle 14, 73–79 (1975)PubMedGoogle Scholar
  29. Dühler, K.D., Wuttke, W.: Total blockade of phasic pituitary prolactin release in rats: effect on serum LH and progesterone during the estrous cycle and pregnancy. Endocrinology 94, 1595–1600 (1974)Google Scholar
  30. Dudley, H.W., Moir, Ch.: The substance responsible for the traditional clinical effect of ergot. Brit. med. J. I, 520–523 (1935)Google Scholar
  31. Embrey, M.P., Garrett, W.J.: A study of the effects of dihydroergotamine on the intact human uterus. J. Obstet. Gynaec. Brit. Emp. 62, 150–154 (1955)PubMedGoogle Scholar
  32. Emmenegger, H., Meier-Ruge, W.: The actions of Hydergine® on the brain. A histochemical, circulatory and neurophysiological study. Pharmacology 1, 65–78 (1968)PubMedGoogle Scholar
  33. Euler, U.S. v., Hesser, C.M.: Beobachtungen über Hemmungen der Sinusdruckreflexe durch Ergotamin, Dihydroergotamin und Hyperventilation. Schweiz. med. Wschr. 77, 20–21 (1947)Google Scholar
  34. Euler, U.S. v., Schmiterlöw, C.G.: The action of ergotamine on the chemical and mechanical reflexes from the carotid sinus region. Acta physiol. pharmacol. scand. 8, 122–133 (1944)Google Scholar
  35. Fanchamps, A.: Migraine and related types of headache — Pathogenesis and Therapy. S. Afr. Practit. 3, 33–40 (1958)Google Scholar
  36. Fanchamps, A., Doepfner, W., Weidmann, H., Cerletti, A.: Pharmakologische Charakterisierung von Deseril®, einem Serotonin-Antagonisten. Schweiz. med. Wschr. 90, 1040–1046 (1960)PubMedGoogle Scholar
  37. Flückiger, E.: Drugs and the control of prolactin secretion. In: Prolactin and Carcinogenesis. Proc. 4th Tenovus Workshop. Boyns, A.R., Griffiths, K. (eds.), pp. 162–180. Cardiff: Alpha Omega Alpha 1972Google Scholar
  38. Flückiger, E.: Pharmacological characterization of CB 154 (bromocriptin). Triangle 14, 153–157 (1975)Google Scholar
  39. Flückiger, E., Billeter, E., Wagner, H.R.: Inhibition of lactation in rabbits by 2-Br-α-ergokryptine-mesilate (CB 154). Arzneimittel-Forsch. 26, 51–53 (1976a)Google Scholar
  40. Flückiger, E., Doepfner, W., Markó, M., Niederer, W.: Effects of ergot alkaloids on the hypothalamic-pituitary axis. Postgrad. med. J. 52 (Suppl. 1), 57–61 (1976b)PubMedGoogle Scholar
  41. Flückiger, E., Lutterbeck, P.M., Wagner, H.R., Billeter, E.: Antagonism of 2-Br-α-ergokryptine-methanesulfonate (CB 154) to certain endocrine actions of centrally active drugs. Experientia (Basel) 28, 924–925 (1972)Google Scholar
  42. Flückiger, E., Wagner, H.R.: 2-Br-α-Ergokryptin: Beeinflussung von Fertilität und Laktation bei der Ratte. Experientia (Basel) 24, 1130–1131 (1968)Google Scholar
  43. Fozard, J.R.: The animal pharmacology of drugs in the treatment of migraine. In: Migraine and Related Headaches. Saxena, P.R. (ed.), pp. 93–118. Rotterdam: Erasmus University 1975aGoogle Scholar
  44. Fozard, J.R.: The animal pharmacology of drugs used in the treatment of migraine. J. Pharm. Pharmacol. 27, 297–321 (1975b)PubMedGoogle Scholar
  45. Frantz, A.G., Kleinberg, D.L., Noel, G.L.: Studies on prolactin in man. Recent Progr. Hormone Res. 28, 527–590 (1972)PubMedGoogle Scholar
  46. Friesen, H., Hwang, P., Guyda, H., Tolis, G., Tyson, J., Myers, R.: A radioimmunoassay for human prolactin. In: Prolactin and Carcinogenesis. Proc. 4th Tenovus Workshop. Boyns, A.R., Griffiths, K. (eds.), pp. 64–80. Cardiff: Alpha Omega Alpha 1972Google Scholar
  47. Gaddum, J.H., Hameed, K.A.: Drugs which antagonise 5-hydroxy-tryptamine. Brit. J. Pharmacol. 9, 240–248 (1954)PubMedGoogle Scholar
  48. Gygax, P., Meier-Ruge, W., Schulz, U., Enz, A.: Experimental studies on the action of metabolic and vasoactive substances in the oligemically disturbed brain. Arzneimittel-Forsch. 26, 1245–1246 (1976)Google Scholar
  49. Hart, I.C.: Effect of 2-bromo-α-ergocryptine on milk yield and the level of prolactin and growth hormone in the blood of the goat at milking. J. Endocr. 57, 179–180 (1973)PubMedGoogle Scholar
  50. Hart, I.C.: The relationship between lactation and the release of prolactin and growth hormone in the goat. J. Reprod. Fertil. 39, 485–499 (1974)PubMedGoogle Scholar
  51. Hill-Samli, M., MacLeod, R.M.: Thyrotropin-releasing hormone blockade of the ergocryptine and apomorphine inhibition of prolactin release in vitro. Proc. Soc. exp. Biol. (N.Y.) 149, 511–514 (1975)Google Scholar
  52. Hökfelt, T., Fuxe, K.: On the morphology and the neuroendocrine role of the hypothalamic catecholamine neurons. In: Brain-Endocrine Interaction. Knigge, K.M., Scott, D.E., Weindl, A. (eds.), pp. 181–223. Basel: Karger 1972Google Scholar
  53. Hool-Zulauf, B., Stürmer, E.: Oxytocic activity of two dihydro-ergot peptide alkaloids on the rabbit uterus in situ. Naunyn-Schmiedeberg’s Arch. Pharmacol. 293, (Suppl.) R 35 (1976)Google Scholar
  54. Hool-Zulauf, B., Stürmer, E.: Oxytocic activity of two dihydrogenated ergot peptide alkaloids on the rabbit uterus in situ. Arzneimittel-Forsch. 27, 2323–2325 (1977)Google Scholar
  55. Iwangoff, P., Enz, A., Chappuis, A.: Inhibition of cAMP-phosphodiesterase of different cat organs by DH-ergotoxine in the micromolar substrate range. Int. Res. Commun. System med. Sci. 3, 403 (1975)Google Scholar
  56. Johnson, A.M., Loew, D.M., Vigouret, J.M.: Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-dopa. Brit. J. Pharmacol. 56, 59–68 (1976)Google Scholar
  57. Johnson, A.M., Vigouret, J.M., Loew, D.M.: Central dopaminergic actions of ergotoxine alkaloids and some derivatives. Experientia (Basel) 29, 763 (1973)Google Scholar
  58. Karg, H., Schams, D., Reinhardt, V.: Effects of 2-Br-α-ergocryptine on plasma prolactin level and milk yield in cows. Experientia (Basel) 28, 574–576 (1972)Google Scholar
  59. Kharasch, M.S., King, H., Stoll, A., Thompson, M.R.: The new ergot alkaloid. Science 83, 206–207 (1936)PubMedGoogle Scholar
  60. Kirchhof, A.C., Racely, C.A., Wilson, W., David, N.A.: An ergonovine-like oxytocic synthesized from lysergic acid. West. J. Surg. 52, 197–208 (1944)Google Scholar
  61. Konzett, H.: Specific antagonism of dibenamine to ergometrine. Ciba Foundation Symposium on Adrenergic Mechanisms. Wolstenholme, G.E.W., O’Connor, M. (eds.), pp. 463–465. London: Churchill 1960Google Scholar
  62. Lance, J.W.: The Mechanism and Management of Headache. London: Butterworths 1969Google Scholar
  63. Lance, J.W.: The pathophysiology and treatment of migraine. N.Z. med. J. 79, 954–960 (1974)PubMedGoogle Scholar
  64. Lieberman, A., Miyamoto, T., Battista, A.F., Goldstein, M.: Studies on the antiparkinsonian efficacy of lergotrile. Neurology (Minneap.) 25, 459–462 (1975)Google Scholar
  65. Loew, D.M., Vigouret, J.M., Jaton, A.L.: Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine. Postgrad. med. J. 52 (Suppl. 1), 40–46 (1976)PubMedGoogle Scholar
  66. Lutterbeck, P.M., Pryor, J.S., Varga, L., Wenner, R.: Treatment of non-puerperal galactorrhea with an ergot alkaloid. Brit. med. J. 3, 228–229 (1971)PubMedGoogle Scholar
  67. MacLeod, R.M., Lehmeyer, J.E.: Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Endocrinology 94, 1077–1085 (1974)PubMedGoogle Scholar
  68. Markó, M., Flückiger, E.: Inhibition of spontaneous and induced ovulation in rats by nonsteroidal agents. Experientia (Basel) 30, 1174–1176 (1974)Google Scholar
  69. Markstein, R., Wagner, H.: The effect of dihydroergotoxin, phentolamine and pindolol on catecholamine-stimulated adenylcyclase in rat cerebral cortex. FEBS Lett. 55, 255–257 (1975)Google Scholar
  70. Markstein, R., Wagner, H.: Effect of dihydroergotoxine on cyclic AMP generating systems in rat cerebral cortex slices. Gerontology (1978) (in press)Google Scholar
  71. Matejcek, M., Devos, J.E.: Selected methods of quantitative EEG analysis and their applications in psychotropic drug research. In: Quantitative Analytic Studies in Epilepsy. Kellaway, P., Petersen, I. (eds.), pp. 183–205. New York: Raven Press 1976Google Scholar
  72. Mayer, P., Schütze, E.: Effect of 2-Br-α-ergokryptine (CB 154) on lactation in the bitch. Experientia (Basel) 29, 484–485 (1973)Google Scholar
  73. Meier, J., Schreier, E.: Human plasma levels of some anti-migraine drugs. Headache 16, 96–104 (1976)PubMedGoogle Scholar
  74. Meier-Ruge, W., Enz, A., Gygax, P., Hunziker, O., Iwangoff, P., Reichlmeier, K.: Experimental pathology in basic research of the aging brain. In: Aging. Gershon, S., Raskin, A. (eds.), Vol. II, pp. 55–126. New York: Raven Press 1975Google Scholar
  75. Mellander, S., Nordenfelt, I.: Comparative effects of dihydroergotamine and noradrenaline on resistance, exchange and capacitance functions in the peripheral circulation. Clin. Sci. 39, 183–201 (1970)PubMedGoogle Scholar
  76. Miller, J.W.: Adrenergic receptors in the myometrium. Ann. N.Y. Acad. Sci. 139, 788–798 (1967)PubMedGoogle Scholar
  77. Miller, M.D., Marshall, J.M.: Uterine response to nerve stimulation; relation to hormonal status and catecholamines. Amer. J. Physiol. 209, 859–865 (1965)PubMedGoogle Scholar
  78. Moir, C.: The action of ergot preparations on the puerperal uterus. Brit. med. J. I, 1119–1122 (1932)Google Scholar
  79. Müller-Schweinitzer, E.: Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine. Naunyn-Schmiedeberg’s Arch. Pharmacol. 292, 113–118 (1976)Google Scholar
  80. Müller-Schweinitzer, E., Stürmer, E.: Investigations on the mode of action of ergotamine in the isolated femoral vein of the dog. Brit. J. Pharmacol. 51, 441–446 (1974)Google Scholar
  81. Nagasawa, H., Yanai, R., Flückiger, E.: Counteraction by 2-Br-α-ergocryptine of pituitary prolactin release promoted by dibutyryladenosine 3′,5′,-monophosphate in rats. In: Human Prolactin. Pasteels, J.L., Robyn, C. (eds.), pp. 313–315. Amsterdam: Excerpta Medica 1973Google Scholar
  82. Niswender, G.D.: Influence of 2-Br-α-ergocryptine on serum levels of prolactin and the estrous cycle in sheep. Endocrinology 94, 612–615 (1974)PubMedGoogle Scholar
  83. Nordenfelt, I., Mellander, S.: Central haemodynamic effects of dihydroergotamine in patients with orthostatic hypotension. Acta med. scand. 191, 115–120 (1972)PubMedGoogle Scholar
  84. Ostfeld, A.M., Chapman, L.F., Goodell, H., Wolff, H.G.: Studies in headache. Summary of evidence concerning a noxious agent active locally during migraine headache. Psychosom. Med. 19, 199–208 (1957)PubMedGoogle Scholar
  85. Owen, D.A.A., Herd, J.K., Kalberer, F., Pacha, W., Salzmann, R.: The influence of ergotamine and methysergide on the storage of biogenic amines. In: Proceedings of the International Headache Symposium, Elsinore, 16–18 May, 1971. Dalessio, D.J., Dalsgaard-Nielsen, T., Diamond, S. (eds.), pp. 153–161. Basle: Sandoz 1971Google Scholar
  86. Owen, D.A.A., Stürmer, E.: The effects of ergotamine and dihydroergotamine on skin and skeletal muscle vasculature. Experientia (Basel) 28, 743 (1972)Google Scholar
  87. Pacha, W., Salzmann, R.: Inhibition of the re-uptake of neuronally liberated noradrenaline and alpha-receptor blocking action of some ergot alkaloids. Brit. J. Pharmacol. 38, 439–440 (1970)Google Scholar
  88. Pasteels, J.L., Danguy, A., Frérotte, M., Ectors, F.: Inhibition de la sécrétion de prolactine par l’ergocornine et la 2-Br-α-ergocryptine: action directe sur l’hypophyse en culture. Ann. Endocr. (Paris) 32, 188–192 (1971)Google Scholar
  89. Pichler, E., Lazarini, W., Filippi, R.: Über schraubenförmige Struktur von Arterien. II. Mitt.: Pharmakologische Strukturanalyse von Hirnarterien. Naunyn-Schmiedeberg’s Arch. exp. Path. Pharmac. 219, 420–439 (1953)Google Scholar
  90. Rothlin, E.: Recherches expérimentales sur l’ergotamine, alcaloide spécifique de l’ergot de seigle. Arch. int. Pharmacodyn. 27, 459–479 (1923)Google Scholar
  91. Rothlin, E.: Beitrag zur differenzierenden Analyse der Mutterkornalkaloide. Schweiz. med. Wschr. 33, 971–975 (1938)Google Scholar
  92. Rothlin, E.: The pharmacology of the natural and dihydrogenated alkaloids of ergot. Bull. schweiz. Akad. med. Wiss. 2, 249–272 (1947)PubMedGoogle Scholar
  93. Rothlin, E., Berde, B.: Über die Wirkung hydrierter Mutterkornalkaloide auf isolierte Muskelstreifen des menschlichen Uterus nahe am Termin, am Termin und wahrend der Geburt. Helv. physiol. pharmacol. Acta 12, 191–205 (1954)PubMedGoogle Scholar
  94. Rothlin, E., Bircher, R.: Allergy, the autonomic nervous system and ergot alkaloids. Progr. Allergy 3, 434–484 (1952)Google Scholar
  95. Rothlin, E., Cerletti, A.: Untersuchungen über die Kreislaufwirkung des Ergotamin. Helv. physiol. pharmacol. Acta 7, 333–370 (1949)PubMedGoogle Scholar
  96. Roubicek, J., Geiger, Ch., Abt, K.: An ergot alkaloid preparation (Hydergine) in geriatric therapy. J. Amer. Geriat. Soc. 20, 222–229 (1972)PubMedGoogle Scholar
  97. Roubicek, J., Matejcek, M., Montague, S.: The EEG in old age. Electroenceph. clin. Neurophysiol. 34, 718 (1973)Google Scholar
  98. Saxena, P.R.: The effects of antimigraine drugs on the vascular responses by 5-hydroxytryptamine and related biogenic substances on the external carotid artery bed of dogs: Possible pharmacological implications to their antimigraine action. Headache 12, 44–54 (1972)PubMedGoogle Scholar
  99. Saxena, P.R.: Selective vasoconstriction in carotid vascular bed by methysergide: Possible relevance to its antimigraine effect. Europ. J. Pharmacol. 27, 99–105 (1974)Google Scholar
  100. Saxena, P.R., Vlaam-Schluter, G.M. de: Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine — studies in an experimental model for migraine. Headache 13, 142–163 (1974)PubMedGoogle Scholar
  101. Schams, D., Reinhardt, V., Karg, H.: Effects of 2-Br-α-ergokryptine on plasma prolactin level during parturition and onset of lactation in cows. Experientia (Basel) 28, 697–699 (1972)Google Scholar
  102. Schmidt, R., Fanchamps, A.: Effect of caffeine on intestinal absorption of ergotamine in man. Europ. J. clin. Pharmacol. 7, 213–216 (1974)Google Scholar
  103. Shelesnyak, M.C.: Ergotoxine inhibition of deciduoma formation and its reversal by progesterone. Amer. J. Physiol. 179, 301–304 (1954)PubMedGoogle Scholar
  104. Shelesnyak, M.C.: Maintenance of gestation in ergotoxine-treated pregnant rats by exogenous prolactin. Acta endocr. (Kbh.) 27, 99–109 (1958)Google Scholar
  105. Sicuteri, F.: Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine. Int. Arch. Allergy 15, 300–307 (1959)PubMedGoogle Scholar
  106. Sinha, Y.N., Salocks, C.B., Lewis, U.J., Vanderlaan, W.P.: Influence of nursing on the release of prolactin and GH in mice with high and low incidence of mammary tumors. Endocrinology 95, 947–954 (1974)PubMedGoogle Scholar
  107. Sinha, Y.N., Selby, F.W., Vanderlaan, W.P.: Effects of ergot drugs on prolactin and growth hormone secretion, and on mammary nucleic acid content in C3H/Bi mice. J. nat. Cancer Inst. 52, 189–191 (1974)PubMedGoogle Scholar
  108. Smith, V.G., Beck, T.W., Convey, E.M., Tucker, H.A.: Bovine serum prolactin, growth hormone, Cortisol and milk yield after ergocryptine. Neuroendocrinology 15, 172–181 (1974)PubMedGoogle Scholar
  109. Stadler, P.A., Stürmer, E.: Comparative studies on the pharmacological properties of stereoisomers of ergotamine and dihydroergotamine. Naunyn-Schmiedeberg’s Arch. Pharmac. 266, 457 (1970)Google Scholar
  110. Stadler, P.A., Stürmer, E.: Synthese und biologische Aktivitäten einiger Stereoisomeren von Ergotamin und Dihydro-ergotamin. Chimia 26, 321 (1972)Google Scholar
  111. Stähelin, H., Burckhardt-Vischer, B., Flückiger, E.: Rat mammary cancer inhibition by a prolactin suppressor, 2-bromo-α-ergokryptine (CB 154). Experientia (Basel) 27, 915–916 (1971)Google Scholar
  112. Stoll, A.: Ergot—a treasure house for drugs. Pharm. J. 194, 605–613 (1965)Google Scholar
  113. Stoll, A., Hofmann, A.: Partialsynthese von Alkaloiden vom Typus des Ergobasins. 6. Mitt. über Mutterkornalkaloide. Helv. chim. Acta 26 (Fasc. 3), 944–965 (1943)Google Scholar
  114. Stürmer, E., Flückiger, E.: In vivo smooth muscle stimulant activity of 2-bromo-α-ergokryptine mesylate (CB 154) as compared with that of ergotamine. Int. Res. Commun. System med. Sci. 2, 1591 (1974)Google Scholar
  115. Suchowsky, G.K., Pegrassi, L.: Action of nicergoline on electroencephalographic recovery after cat brain ischemia. Naunyn-Schmiedeberg’s Arch. Pharmacol. 284, 311–318 (1974)Google Scholar
  116. Takahara, J., Arimura, A., Schally, A.V.: Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophysial portal vessel. Endocrinology 95, 462–465 (1974)PubMedGoogle Scholar
  117. Tashjian, A.H., Hoyt, R.F.: Transient control on organ specific functions in pituitary cells in culture. In: Molecular Genetics and Development Biology. Sussman, M. (ed.), pp. 353–387. New Jersey: Englewood Cliffs 1972Google Scholar
  118. Thorner, M.O., Besser, G.M.: Successful treatment of acromegaly with bromocriptine. Postgrad. med. J. 52 (Suppl. 1), 71–74 (1976)PubMedGoogle Scholar
  119. Toda, N., Fujita, Y.: Responsiveness of isolated cerebral and peripheral arteries to serotonin, norepinephrine and transmural electrical stimulation. Circulat. Res. 33, 98–104 (1973)PubMedGoogle Scholar
  120. Weidmann, H., Taeschler, M.: Influence des substances antimigraineuses sur les effets des catécholamines, de la sérotonine et de la stimulation des nerfs sympathiques. Discussion du mode d’action des antimigraineux. In: Symposium International sur les Céphalées Vasculaires, St. Germain-en-Laye, 15–16 octobre, 1966, pp. 33–40Google Scholar
  121. Wolff, H.G: Pain mechanisms and headache. Triangle 2, 53–64 (1955)Google Scholar
  122. Wolff, H.G.: Headache and Other Head Pain. London-New York: Oxford U. Pr. 1963Google Scholar
  123. Yanai, R., Nagasawa, H.: Effects of ergocornine and 2-Br-α-ergokryptin (CB-154) on the formation of mammary hyperplastic alveolar nodules and the pituitary prolactin levels in mice. Experientia (Basel) 26, 649–650 (1970)Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1978

Authors and Affiliations

  • B. Berde
  • E. Stürmer

There are no affiliations available

Personalised recommendations